Literature DB >> 1699199

The Evi-1 zinc finger myeloid transforming gene is normally expressed in the kidney and in developing oocytes.

K Morishita1, E Parganas, D M Parham, T Matsugi, J N Ihle.   

Abstract

Activation of the Evi-1 zinc finger gene is commonly associated with the transformation of murine leukemias and is involved in some cases of human AML involving rearrangements at chromosome 3q25. To determine the normal function of the gene, we have looked for expression in a variety of cell lines and tissues. The predominant sites of expression of the gene are in the kidney and ovary. In the kidney, expression is localized to the renal tubules in the corticomedullary junction. In the ovary, high levels of the Evi-1 protein are found in the cytoplasm of developing oocytes. The latter result suggests a potential role for the Evi-1 gene product in early oocyte development.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1699199

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  17 in total

1.  Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26.

Authors:  K Morishita; E Parganas; C L William; M H Whittaker; H Drabkin; J Oval; R Taetle; M B Valentine; J N Ihle
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

Review 2.  Molecular insights into segmentation along the proximal-distal axis of the nephron.

Authors:  Raphael Kopan; Hui-Teng Cheng; Kameswaran Surendran
Journal:  J Am Soc Nephrol       Date:  2007-06-13       Impact factor: 10.121

3.  A mouse oocyte-specific protein that binds to a region of mZP3 promoter responsible for oocyte-specific mZP3 gene expression.

Authors:  M Schickler; S A Lira; R A Kinloch; P M Wassarman
Journal:  Mol Cell Biol       Date:  1992-01       Impact factor: 4.272

4.  Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression.

Authors:  Hiromi Yuasa; Yuichi Oike; Atsushi Iwama; Ichiro Nishikata; Daisuke Sugiyama; Archibald Perkins; Michael L Mucenski; Toshio Suda; Kazuhiro Morishita
Journal:  EMBO J       Date:  2005-05-12       Impact factor: 11.598

5.  MECOM-associated syndrome: a heterogeneous inherited bone marrow failure syndrome with amegakaryocytic thrombocytopenia.

Authors:  Manuela Germeshausen; Phil Ancliff; Jaime Estrada; Markus Metzler; Eva Ponstingl; Horst Rütschle; Dirk Schwabe; Richard H Scott; Sule Unal; Angela Wawer; Bernward Zeller; Matthias Ballmaier
Journal:  Blood Adv       Date:  2018-03-27

6.  Retroviral insertions 90 kilobases proximal to the Evi-1 myeloid transforming gene activate transcription from the normal promoter.

Authors:  C Bartholomew; J N Ihle
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

7.  Four of the seven zinc fingers of the Evi-1 myeloid-transforming gene are required for sequence-specific binding to GA(C/T)AAGA(T/C)AAGATAA.

Authors:  R Delwel; T Funabiki; B L Kreider; K Morishita; J N Ihle
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

8.  Expression of the Evi-1 zinc finger gene in 32Dc13 myeloid cells blocks granulocytic differentiation in response to granulocyte colony-stimulating factor.

Authors:  K Morishita; E Parganas; T Matsugi; J N Ihle
Journal:  Mol Cell Biol       Date:  1992-01       Impact factor: 4.272

9.  Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias.

Authors:  T Tanaka; K Mitani; M Kurokawa; S Ogawa; K Tanaka; J Nishida; Y Yazaki; Y Shibata; H Hirai
Journal:  Mol Cell Biol       Date:  1995-05       Impact factor: 4.272

10.  Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity.

Authors:  Keisuke Kataoka; Tomohiko Sato; Akihide Yoshimi; Susumu Goyama; Takako Tsuruta; Hiroshi Kobayashi; Munetake Shimabe; Shunya Arai; Masahiro Nakagawa; Yoichi Imai; Keiki Kumano; Katsuyoshi Kumagai; Naoto Kubota; Takashi Kadowaki; Mineo Kurokawa
Journal:  J Exp Med       Date:  2011-11-14       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.